LiDCO has provided an update on how its technology is being used to treat Covid-19 patients more effectively using two of its guided clinical protocols that are, uniquely, pre-loaded on LiDCO’s monitors. It has also quantified Q1 sales, which came in at £4.4m, significantly ahead of H1-20 revenues of £3.5m and providing a very strong start to the year. When added to revenues under the HUP and other contracted revenues, we estimate LiDCO already has coverage of ~80% of our FY
05 May 2020
Hemodynamic management in COVID-19 patients & Q1 sales update
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Hemodynamic management in COVID-19 patients & Q1 sales update
- Published:
05 May 2020 -
Author:
Chris Glasper -
Pages:
3
LiDCO has provided an update on how its technology is being used to treat Covid-19 patients more effectively using two of its guided clinical protocols that are, uniquely, pre-loaded on LiDCO’s monitors. It has also quantified Q1 sales, which came in at £4.4m, significantly ahead of H1-20 revenues of £3.5m and providing a very strong start to the year. When added to revenues under the HUP and other contracted revenues, we estimate LiDCO already has coverage of ~80% of our FY